EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Galectin-3, Inflammation, and the Risk of Atrial High-Rate Episodes in Patients with Dual Chamber Pacemakers

Gelu Radu Simu, Raluca Tomoaia iD, Radu Ovidiu Rosu, Gabriel Gusetu, Mihai Puiu, Gabriel Cismaru iD, Bogdan Caloian, Andreea Terec, Teodor Buliga, Armand Boer, Ioan Alexandru Minciuna, Gyorgy Bodizs und 2 weitere

International Journal of Molecular Sciences · 2023

DOI: 10.3390/ijms24097710 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Gelu Radu Simu und 13 weiteren Autor:innen. Beteiligte Einrichtung: 5th Department of Internal Medicine, Faculty of Medicine, "Iuliu Hațieganu" University of Medicine and Pharmacy, 400012 Cluj-Napoca, Romania. Hauptthemen laut MEDLINE: Atrial Fibrillation, Defibrillators, Implantable, Pacemaker, Artificial. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Iuliu Hațieganu University of Medicine and Pharmacy, “Iuliu Hatieganu” University of Medicine and Pharmacy.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Atrial high-rate episodes (AHREs) are atrial tachyarrhythmias that are exclusively detected by cardiac implantable electronic devices (CIEDs) with an atrial lead. The objective of this study was to investigate the incidence and predictive factors for AHREs, and to evaluate the ability of inflammation biomarkers to predict the occurrence of AHREs. 102 patients undergoing CIED procedure who received a dual chamber pacemaker were included. CIED interrogation was performed 1 year after the implantation procedure. Patients were divided into groups according to the occurrence of AHREs, which was the primary endpoint of the study. The mean age of the patients was of 73 ± 8.6 years and 48% were male. The incidence of AHREs was 67% at 1 year follow-up. Patients with AHREs were older, had higher left atrial indexed volume (LAVi), higher baseline galectin-3 levels (1007.5 ± 447.3 vs. 790 ± 411.7 pg/mL) and received betablockers more often, along with amiodarone and anticoagulants. Interestingly, the CHADSVASC score did not differ significantly between the two groups. A cut-off value of galectin > 990 pg/mL predicted AHREs with moderate accuracy (AUC of 0.63, 95% CI 0.52 to 0.73, p = 0.04), and this association was confirmed in the univariate regression analysis (OR 1.0012, 95% CI 1.0001 to 1.0023, p = 0.0328). However, based on the multivariate regression analysis, galectin lost its prognostic significance under the effect of LAVi, which remained the only independent predictor of AHREs (OR 1.0883, 95% CI 1.0351 to 1.1441, p = 0.0009). AHREs are common in CIEDs patients. Galectin-3 may bring additional data in the prediction of AHREs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Atrial FibrillationDefibrillators, ImplantablePacemaker, ArtificialHumansMaleMiddle AgedAgedAged, 80 and overFemaleGalectin 3InflammationRisk Factors

Stichwörter der Autor:innen

AHREsatrial high-rate episodesgalectin-3inflammation

Substanzen

Galectin 3

Autor:innen und Institutionen

  • 5th Department of Internal Medicine, Faculty of Medicine, "Iuliu Hațieganu" University of Medicine and Pharmacy, 400012 Cluj-Napoca, Romania.
  • Cardiology Department, Rehabilitation Hospital, 400347 Cluj-Napoca, Romania.
  • Clinical Laboratory, Rehabilitation Hospital, 400347 Cluj-Napoca, Romania.

ORCID-Profile: Raluca Tomoaia, Gabriel Cismaru

Förderung

  • Iuliu Hațieganu University of Medicine and Pharmacy
  • “Iuliu Hatieganu” University of Medicine and Pharmacy

Zitieren

APA

Simu, G. R., Tomoaia, R., Rosu, R. O., Gusetu, G., Puiu, M., Cismaru, G., Caloian, B., Terec, A., Buliga, T., Boer, A., Minciuna, I. A., Bodizs, G., Zdrenghea, D., & Pop, D. (2023). Galectin-3, Inflammation, and the Risk of Atrial High-Rate Episodes in Patients with Dual Chamber Pacemakers. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms24097710

Vancouver

Simu GR, Tomoaia R, Rosu RO, Gusetu G, Puiu M, Cismaru G, et al. Galectin-3, Inflammation, and the Risk of Atrial High-Rate Episodes in Patients with Dual Chamber Pacemakers. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms24097710

BibTeX
@article{Simu2023,
  author = {Simu, Gelu Radu and Tomoaia, Raluca and Rosu, Radu Ovidiu and Gusetu, Gabriel and Puiu, Mihai and Cismaru, Gabriel and Caloian, Bogdan and Terec, Andreea and Buliga, Teodor and Boer, Armand and Minciuna, Ioan Alexandru and Bodizs, Gyorgy and Zdrenghea, Dumitru and Pop, Dana},
  title = {Galectin-3, Inflammation, and the Risk of Atrial High-Rate Episodes in Patients with Dual Chamber Pacemakers},
  journal = {International Journal of Molecular Sciences},
  year = {2023},
  doi = {10.3390/ijms24097710}
}
Kostenlos starten →